BioLine RX Price To Book vs. Current Valuation
| BLRX Stock | ILS 8.10 0.10 1.25% |
For BioLine RX profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLine RX to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLine RX utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLine RX's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLine RX over time as well as its relative position and ranking within its peers.
BioLine |
BioLine RX Current Valuation vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioLine RX's current stock value. Our valuation model uses many indicators to compare BioLine RX value to that of its competitors to determine the firm's financial worth. BioLine RX is number one stock in price to book category among its peers. It also is the top company in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLine RX by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLine RX's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BioLine Current Valuation vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
BioLine RX |
| = | 0.77 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
BioLine RX |
| = | (13.02 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
BioLine Current Valuation vs Competition
BioLine RX is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 792.35 Million. BioLine RX has negative current valuation of (13.02 Million) contributing less than 1% to the industry.
BioLine RX Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioLine RX, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioLine RX will eventually generate negative long term returns. The profitability progress is the general direction of BioLine RX's change in net profit over the period of time. It can combine multiple indicators of BioLine RX, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.
BioLine Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioLine RX. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioLine RX position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioLine RX's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in BioLine RX without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Use Investing Themes to Complement your BioLine RX position
In addition to having BioLine RX in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Thematic Idea Now
Healthcare
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Healthcare theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BioLine Stock
To fully project BioLine RX's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioLine RX at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioLine RX's income statement, its balance sheet, and the statement of cash flows.